Erbitux plus chemo extends colon cancer survival, trial shows

09/23/2009 | Reuters

Combining Erbitux with chemotherapy significantly extends survival rates for colon cancer patients who have a specific genetic profile, according to results of the CRYSTAL trial. Study data showed patients with the normal, or wild-type, version of the KRAS gene had median survival rates of 23.5 months, compared with 20 months on chemotherapy alone.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI